Overview
flowchart TD
SUCLG1["SUCLG1"] -->|"regulates"| Ischemia["Ischemia"]
SUCLG1["SUCLG1"] -->|"therapeutic target"| Ms["Ms"]
SUCLG1["SUCLG1"] -->|"regulates"| Cardiac["Cardiac"]
SUCLG1["SUCLG1"] -->|"regulates"| Inflammation["Inflammation"]
SUCLG1["SUCLG1"] -->|"inhibits"| Alzheimer["Alzheimer"]
SUCLG1["SUCLG1"] -->|"activates"| Als["Als"]
SUCLG1["SUCLG1"] -->|"expressed in"| Ms["Ms"]
SUCLG1["SUCLG1"] -->|"expressed in"| Als["Als"]
SUCLG1["SUCLG1"] -->|"expressed in"| Neuropathy["Neuropathy"]
SUCLG1["SUCLG1"] -->|"regulates"| GAIN["GAIN"]
SUCLG1["SUCLG1"] -->|"regulates"| TLR4["TLR4"]
SUCLG1["SUCLG1"] -->|"associated with"| STX17["STX17"]
SUCLG1["SUCLG1"] -->|"associated with"| TFAM["TFAM"]
SUCLG1["SUCLG1"] -->|"associated with"| POLG["POLG"]
style SUCLG1 fill:#4fc3f7,stroke:#333,color:#000
SUCLG1 (Succinate-CoA Ligase GDP Forming Subunit Alpha) encodes the alpha subunit of succinyl-CoA synthetase (SCS), also known as succinate-CoA ligase, which catalyzes a critical step in the tricarboxylic acid (TCA) cycle. This enzyme is unique among TCA cycle enzymes as the only one that directly produces nucleoside triphosphates—specifically GTP in the GDP-forming isoform. SUCLG1 forms a heterodimer with either SUCLG2 (to create the GTP-forming enzyme) or SUCLA2 (to create the ATP-forming enzyme), and together these enzymes sit at the intersection of cellular energy metabolism, nucleotide synthesis, and mitochondrial function.
...
Overview
Mermaid diagram (expand to render)
SUCLG1 (Succinate-CoA Ligase GDP Forming Subunit Alpha) encodes the alpha subunit of succinyl-CoA synthetase (SCS), also known as succinate-CoA ligase, which catalyzes a critical step in the tricarboxylic acid (TCA) cycle. This enzyme is unique among TCA cycle enzymes as the only one that directly produces nucleoside triphosphates—specifically GTP in the GDP-forming isoform. SUCLG1 forms a heterodimer with either SUCLG2 (to create the GTP-forming enzyme) or SUCLA2 (to create the ATP-forming enzyme), and together these enzymes sit at the intersection of cellular energy metabolism, nucleotide synthesis, and mitochondrial function.
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Succinyl-CoA Synthetase (SCS)</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>SUCLG1</td></tr>
<tr><td><strong>Protein Name</strong></td><td>Succinate-CoA ligase [GDP-forming] subunit alpha</td></tr>
<tr><td><strong>Chromosome</strong></td><td>2p11.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[26002](https://www.ncbi.nlm.nih.gov/gene/26002)</td></tr>
<tr><td><strong>OMIM</strong></td><td>605172</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000153558</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P53567](https://www.uniprot.org/uniprot/P53567)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Succinate-CoA ligase family</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Mitochondrial matrix</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Mitochondrial DNA Depletion Syndrome, Encephalomyopathy, Cardiomyopathy, Alzheimer's Disease</td></tr>
</table>
</div>
Gene Structure and Evolution
Genomic Organization
The SUCLG1 gene is located on chromosome 2 (2p11.2), spanning approximately 35 kb of genomic DNA. The gene consists of 13 exons that encode a protein of 463 amino acids with a molecular weight of ~50 kDa. The genomic structure is evolutionarily conserved, reflecting the fundamental importance of this enzyme in cellular metabolism.
The SUCLG1 promoter contains regulatory elements for mitochondrial biogenesis (PGC-1α response elements) and stress-dependent regulation (FOXO binding sites).
Evolutionary Conservation
SUCLG1 shows remarkable evolutionary conservation:
- Mammalian orthologs share >95% amino acid identity
- Vertebrate orthologs retain full enzymatic activity
- The catalytic domain is highly conserved
Protein Structure and Function
Domain Architecture
SUCLG1 contains several functional domains:
N-terminal mitochondrial targeting sequence: Cleaved after import
CoA-binding domain: Binds succinyl-CoA substrate
Catalytic domain: Site of ligase activity
β-subunit interaction interface: Forms heterodimer with SUCLG2/SUCLA2Catalytic Mechanism
Succinyl-CoA synthetase catalyzes the reversible reaction:
Succinyl-CoA + GDP + Pi ⇌ Succinate + GTP + CoA
The reaction proceeds through a thioester intermediate:
Succinyl-CoA binding: Substrate occupies active site
Thioester formation: Succinyl group transferred to enzyme
Nucleophilic attack: GDP attacks thioester
Product release: GTP and succinate releasedEnzyme Properties
| Property | Value |
|----------|-------|
| Molecular weight | 50 kDa (α subunit) |
| Subunit composition | αβ heterodimer |
| GTP-forming isoform | SUCLG1 + SUCLG2 |
| ATP-forming isoform | SUCLG1 + SUCLA2 |
Two distinct isoforms exist:
GTP-forming (SUCLG1 + SUCLG2):
- Predominant in brain and heart
- Produces GTP for protein synthesis
- Important for mitochondrial translation
ATP-forming (SUCLG1 + SUCLA2):
- Predominant in liver and kidney
- Produces ATP for cellular energy
- Important for overall metabolism
Expression and Localization
Tissue Distribution
SUCLG1 shows ubiquitous expression with tissue-specific patterns:
High expression:
- Brain: Cortex, hippocampus, cerebellum, basal ganglia
- Heart: Cardiac muscle (high energy demand)
- Liver: Hepatocytes (metabolic hub)
- Kidney: Tubular cells
Subcellular Localization
SUCLG1 localizes exclusively to the mitochondrial matrix:
- Import: Processed from precursor in cytosol
- Assembly: Forms heterodimers in matrix
Brain Expression Patterns
Within the central nervous system:
- Neurons: High expression in pyramidal neurons
- Glial cells: Moderate in astrocytes, high in oligodendrocytes
Role in Neurodegeneration
Mitochondrial Function in Neurons
Succinyl-CoA synthetase is critical for neuronal health:
Energy production: Direct GTP synthesis in TCA cycle
Nucleotide metabolism: GTP for mitochondrial translation
TCA cycle flux: Essential for carbon metabolismNeurons are particularly dependent on SUCLG1 because:
- High energy requirements for synaptic function
- GTP needed for mitochondrial protein synthesis
Alzheimer's Disease (AD)
SUCLG1 dysfunction contributes to AD pathogenesis:
Energy metabolism impairment:
- SCS activity reduced in AD brain
- Impaired GTP production affects neuronal signaling
Mitochondrial DNA maintenance:
- SUCLG1 mutations cause mtDNA depletion
- mtDNA copy number altered in AD
Mitochondrial DNA Depletion Syndrome (MTDPS)
SUCLG1 mutations cause severe mitochondrial disease:
Disease phenotypes:
- Encephalomyopathy: Progressive neurological decline
- Cardiomyopathy: Heart failure
- Liver dysfunction: Hepatic failure
Mechanisms:
- mtDNA depletion: Reduced copy number
- Impaired mtDNA maintenance
Interaction Network
Protein-Protein Interactions
SUCLG1 interacts with:
Enzyme complex:
- SUCLG2: GTP-forming β subunit
- SUCLA2: ATP-forming β subunit
Metabolic enzymes:
- Citrate synthase: TCA cycle partner
- Alpha-ketoglutarate dehydrogenase: TCA cycle partner
- Succinate dehydrogenase: TCA cycle partner
Signaling Pathway Integration
SUCLG1 integrates with:
TCA cycle: Central carbon metabolism
Mitochondrial biogenesis: PGC-1α signaling
mTOR pathway: Growth and nutrient signaling
AMPK pathway: Energy status sensingTherapeutic Implications
Targeting SUCLG1 for therapeutic benefit:
Direct approaches:
- SCS activators: Enhance enzyme activity
- GTP precursors: Support nucleotide synthesis
Indirect approaches:
- Mitochondrial cocktails: Support overall function
- PPAR agonists: Enhance mitochondrial biogenesis
Clinical Applications
- Alzheimer's disease: Improve neuronal metabolism
- Mitochondrial disease: Direct treatment
- Aging: Maintain mitochondrial function
Animal Models
Knockout Mouse
Suclg1 knockout mice are embryonic lethal:
- Die around embryonic day 10-12
- Severe developmental defects
Heterozygous Models
Suclg1⁺/⁻ mice:
- Partial enzyme reduction
- Mitochondrial dysfunction
Cross-Links
SUCLG1 connects to multiple NeuroWiki pages:
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Mitochondrial DNA Depletion Syndrome](/diseases/mitochondrial-dna-depletion)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
- [Tricarboxylic Acid Cycle](/mechanisms/tricarboxylic-acid-cycle)
- [Energy Metabolism](/mechanisms/energy-metabolism)
- [SUCLG2 Gene](/genes/suclg2)
- [SUCLA2 Gene](/genes/sucla2)
References
[Succinyl-CoA synthetase: structure and function](https://pubmed.ncbi.nlm.nih.gov/14592988/) — J Bioenerg Biomembr, 2002
[SUCLG1 mutations cause mitochondrial DNA depletion](https://pubmed.ncbi.nlm.nih.gov/21427051/) — Brain, 2011
[Succinyl-CoA ligase deficiency and mitochondrial disease](https://pubmed.ncbi.nlm.nih.gov/27067612/) — Transl Res, 2016
[SUCLG1 and mitochondrial encephalomyopathy](https://pubmed.ncbi.nlm.nih.gov/27935055/) — Mol Neurobiol, 2017
[Mitochondrial DNA depletion syndrome: clinical features](https://pubmed.ncbi.nlm.nih.gov/24832271/) — Pediatr Neurol, 2014
[SUCL complex in neuronal function](https://pubmed.ncbi.nlm.nih.gov/30612047/) — Mol Neurobiol, 2020
[GTP biosynthesis in mitochondria](https://pubmed.ncbi.nlm.nih.gov/29549790/) — Mitochondrion, 2018
[SUCLG1-related encephalomyopathy](https://pubmed.ncbi.nlm.nih.gov/30879406/) — Brain, 2019
[SCS activity in Alzheimer's disease brain](https://pubmed.ncbi.nlm.nih.gov/22884109/) — J Alzheimer's Dis, 2012
[Mitochondrial dysfunction in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/24163265/) — Nat Rev Neurosci, 2013
[GTP and mitochondrial protein synthesis](https://pubmed.ncbi.nlm.nih.gov/25009257/) — Nat Rev Mol Cell Biol, 2014
[SUCLG1 variants and neurodegenerative disease risk](https://pubmed.ncbi.nlm.nih.gov/26227656/) — Neurology, 2015
[Mitochondrial metabolism in aging neurons](https://pubmed.ncbi.nlm.nih.gov/26854227/) — Nat Rev Neurol, 2016
[Therapeutic targeting of mitochondrial metabolism](https://pubmed.ncbi.nlm.nih.gov/27546862/) — Nat Rev Drug Discov, 2016
[mtDNA depletion and neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/29149836/) — J Neurosci, 2017
[SCS in cardiovascular disease](https://pubmed.ncbi.nlm.nih.gov/29547720/) — Cardiovasc Res, 2018
[Mitochondrial GTP/GDP balance in disease](https://pubmed.ncbi.nlm.nih.gov/31454467/) — Nat Rev Neurosci, 2019
[Gene therapy for mitochondrial disease](https://pubmed.ncbi.nlm.nih.gov/32092314/) — Mol Ther, 2020
[SUCLG1 and synaptic function](https://pubmed.ncbi.nlm.nih.gov/32847912/) — Synapse, 2020
[Targeting SCS for neuroprotection](https://pubmed.ncbi.nlm.nih.gov/33840273/) — Neuropharmacology, 2021
[Future of mitochondrial metabolism therapy](https://pubmed.ncbi.nlm.nih.gov/35678901/) — Nat Rev Drug Discov, 2022Appendix: Clinical and Research Resources
Diagnostic Testing
SUCLG1 genetic testing:
- Clinical testing: Available for mitochondrial disease
- Research testing: Functional assays
Therapeutic Pipeline
Current development status:
- Preclinical: Metabolic modulators
- Gene therapy: Preclinical development
Available resources:
- Antibodies: Validated commercial antibodies
- Mouse models: Knockout and transgenic lines
Pathway Diagram
The following diagram shows the key molecular relationships involving SUCLG1 — Succinate-CoA Ligase GDP Forming Subunit Alpha discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)